Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November
After the company updated the timeline for filing its pain-relieving drug for approval from the Food and Drug Administration, and presented early-stage study results for its solid-tumor cancer drug at the 2017 Society for Immunotherapy of Cancer (SITC) annual meeting, Nektar Therapeutics' (NASDAQ: NKTR) shares skyrocketed 124% in November, according to S&P Global Market Intelligence.
On Nov. 7, Nektar Therapeutics reported third-quarter financial results that were bolstered by a $150 million up-front payment from Eli Lilly relating to their partnership on NKTR-358, a pre-clinical-stage autoimmune-disease therapy. The company recognized $128 million of that payment, so revenue grew to $152.9 million from $36.3 million in third-quarter 2016. Operating costs were $83.4 million, up from $69.2 million year over year, and cash and investments finished the quarter at $412.2 million.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Nektar Therapeutics Aktie
Die Community sieht Nektar Therapeutics leicht positiv: Mehr Buy- als Sell-Einschätzungen.
Ein prognostiziertes Kursziel von 2 € für Nektar Therapeutics zeigt ein Potenzial von über 50% im Vergleich zum aktuellen Kurs von 1.25 €.
